相关实验视频

Updated: Jun 9, 2025

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

在帕金森病的血清α klotho水平

Ahmet Yalcin¹, Emine Gemci², Busra Yurumez²

¹Geriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey. ahmetemreyalcin@hotmail.com.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|October 29, 2024

概括

抗衰老蛋白质alpha-Klotho (α-Klotho) 的血清水平在帕金森病患者中明显较低.

科学领域:

神经科学是一个神经科学.
老年学是一门学科.
生物化学生化学

背景情况:

帕金森病 (PD) 是一种具有显著发病率的衰弱性神经退行性疾病.
抗衰老蛋白Alpha-Klotho (α-Klotho) 具有神经保护性,因此越来越引起研究兴趣.
了解PD的生物标志物对于早期诊断和管理至关重要.

研究的目的:

研究和比较帕金森病 (PD) 患者的血清α-Klotho水平与健康对照.
为了探索α-Klotho水平和PD患者的认知功能之间的关联.

主要方法:

一项涉及157名PD患者和157名对照者的横截面病例控制研究.
用英国帕金森病学会大脑银行标准确认了PD诊断.
血清α-Klotho水平使用商业酶相关免疫吸收试验 (ELISA) 来量化.

主要成果:

与对照组相比,PD患者的血清α-Klotho水平显著降低 (0.85nmol/L) (1.47nmol/L,p<0.001).与对照组相比,PD患者的血清α-Klotho水平显著降低 (0.85nmol/L).
在患有痴呆症的PD患者中,与没有痴呆症的患者相比,也观察到较低的α-Klotho水平.
逻辑回归表明α-Klotho是PD的显著预测因子 (OR:0.04,p < 0.001),灵敏度为90%和特异性为65%.

结论:

血清α-Klotho可能作为帕金森病的潜在诊断生物标志物.
需要进一步的研究来验证这些发现,并探索α-Klotho在PD中的治疗潜力.

关键词:

痴呆症是一种痴呆症.年龄较大的个人.帕金森病是帕金森氏症的一种疾病.α-Klotho 蛋白质是一种

更多相关视频

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...